Strong Financial Performance
Fresenius reported high single-digit organic revenue and earnings growth with a 9% increase in group organic revenue and a 9% rise in EBIT before special items. Operating cash flow reached over EUR 760 million, and the company continued to lower leverage, ending the quarter at 3.24x net debt to EBITDA.
Kabi Segment Success
Kabi's revenue grew organically by 11% year-on-year, driven by strong performance in biopharma with a 66% increase. Kabi's EBIT margin improved to 15.9%, a significant year-over-year margin improvement of 160 basis points.
Helios Revenue Growth
Helios reported an 8% organic revenue growth, with Helios Germany achieving an 8% growth and a margin of 8.8%. Year-to-date, Helios Spain delivered a strong margin of 11.2%.
Upgraded Financial Outlook
Fresenius upgraded its guidance, now expecting 6% to 8% organic revenue growth and 8% to 11% EBIT growth for the full year 2024.